Vitreous composition modification after transpalpebral electrical stimulation of the eye: Biochemical analysis

Colombo, Leonardo; Caretti, Anna; Dei, Michele; Luciano, Francesco; Romano, Dario; Paroni, Rita; Patelli, Fabio; Ghidoni, Riccardo; Rossetti, Luca

doi:10.1016/j.exer.2021.108601

Cited by 2 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1755, Le Roy provoked phosphenes in a blind patient by sending electric current pulses through a wire wound around the head (Paulus 2010 ). Since then, various techniques have been established in order to apply electrical stimulation to the retina and the optic nerve via transcutaneous, transpalpebral, transcorneal, or transscleral applications (Colombo et al 2021 ; Gall et al 2016 ; Inomata et al 2008 ; Rock et al 2017 ). Safety data indicated non-significant risks associated with electrical stimulation of the eye (Antal et al 2017 ; Fu et al 2015 ; Rahmatnejad et al 2016 ).…”

Section: Discussionmentioning

confidence: 99%

Electrical neurostimulation in glaucoma with progressive vision loss

Erb¹,

Eckert²,

Gindorf³

et al. 2022

Bioelectron Med

View full text Add to dashboard Cite

Background The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. Methods Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraocular pressure (IOP) underwent electrical ONS. Closed eyes were separately stimulated by bipolar rectangular pulses with stimulus intensities up to 1.2 mA sufficient to provoke phosphenes. Ten daily stimulation sessions within 2 weeks lasted about 80 min each. Right before ONS at baseline (PRE), vision loss was documented by static threshold perimetry and compared to the same assessment approximately 1 year afterwards (POST). Mean defect (MD) was defined as primary outcome parameter. Perimetries with a reliability factor (RF) of max. 20% were considered. Results Perimetry follow-up of 101 eyes in 70 patients fulfilled the criterion of a max. 20% RF. Follow-up was performed on average 362.2 days after ONS. MD significantly decreased from PRE 14.0 dB (median) to POST 13.4 dB (p < 0.01). 64 eyes in 49 patients showed constant or reduced MD as compared to baseline (PRE 13.4 dB vs. POST 11.2 dB). In 37 eyes of 30 patients, MD increased from PRE 14.9 dB to POST 15.6 dB. Conclusions Innovative treatments that preserve visual function through mechanisms other than lowering IOP are required for glaucoma with progressive vision loss. The present long-term data document progression halt in more than 63% of affected eyes after ONS and, thus, extend existing evidence from clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Electrical neurostimulation in glaucoma with progressive vision loss

Erb¹,

Eckert²,

Gindorf³

et al. 2022

Bioelectron Med

View full text Add to dashboard Cite

show abstract

“…In twenty-eight patients with planned vitrectomy, thirteen received microcurrent pre-operatively. In treatment patients, positive effects on retinal cell function and survival, and reduced proinflammatory cytokines (IL-6, IL-8), and reduced bioactive lipid mediator expression (lysophosphatidylcholine), compared to 15 patients who did not receive microcurrent [ 14 ]. An early study demonstrated that transpalpebral microstimulation could be safely administered to patients with dry AMD, treating 25 eyes in seventeen patients receiving two to ten weekly treatments, finding improvement in visual acuity in 52% of eyes, but deteriorations in 26% [ 15 ].…”

mentioning

confidence: 99%

Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation

Parkinson¹,

Sayre²,

Tobe³

2023

Int J Retin Vitr

View full text Add to dashboard Cite

Background To assess micro current to improve vision for dry age-related macular degeneration. Dry age-related macular degeneration is a major cause of blindness, disability, and severe erosion of quality of life, throughout the world. Beyond nutritional supplementation, there is no approved therapy. Methods This was a prospective randomized sham controlled clinical trial for participants with confirmed dry AMD with documented visual loss. Participants were randomized three to one, to receive transpalpebral external micro current electrical stimulation with the MacuMira device. The Treatment group received four treatments in the first two weeks, and two further treatments at weeks 14 and 26. Differences in BCVA and contrast sensitivity (CS) were estimated with mixed-effects repeated measures analysis of variance. Results Change of visual acuity with ETDRS assessment of number of letters read (NLR) and contrast sensitivity at week 4 and 30, compared to the first visit, between 43 treatment and 19 sham control participants. The Sham Control group had NLR of 24.2 (SD 7.1) at baseline, 24.2 (SD 7.2) at 4 weeks, and 22.1 (SD7.4) at 30 weeks. The Treatment group had NLR of 19.6 (SD 8.9) at baseline, 27.6 (SD 9.1) at 4 weeks, and 27.8 (SD 8.4) at 30 weeks. The change in NLR from baseline in the Treatment compared to the Sham control group was 7.7 (95% CI 5.7, 9.7, p < 0.001) at 4 weeks and 10.4 (95% CI 7.8, 13.1, p < 0.001) at 30 weeks. There were similar benefits in CS. Conclusions This pilot study of transpalpebral microcurrent demonstrated improved visual measures and is very encouraging as a potential treatment for dry AMD. Trial Registration: NCT02540148, ClinicalTrials.gov.

show abstract

Vitreous composition modification after transpalpebral electrical stimulation of the eye: Biochemical analysis

Cited by 2 publications

References 40 publications

Electrical neurostimulation in glaucoma with progressive vision loss

Electrical neurostimulation in glaucoma with progressive vision loss

Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation

Contact Info

Product

Resources

About